Brian Pepin’s Post

Roche has announced results from its Phase IIb PADOVA study evaluating prasinezumab in patients with early-stage Parkinson’s disease. While the primary endpoint of time to confirmed motor progression did not reach statistical significance, the drug demonstrated promising trends in several secondary and exploratory endpoints. ➡️ https://hubs.li/Q030Z6dg0 #pharmanews #parkinsons #clinicalstudy

Rare disease research faces a common challenge: how do you study new treatments and advance research when there aren’t a lot of people living with the rare disease? And how do you incentivize drug development sponsors to invest in these important studies and encourage patients to participate in clinical trials? #RareDisease #ClinicalTrials #PatientVoice

Last call! Don't miss out on our May 16 webinar exploring Parkinson’s disease endpoint data collection! Our experts will delve into topics that include: -Sensitivity of digital measures in disease progression monitoring -Efficacy and quality of life evaluations using clinical scales and patient-reported outcomes -Imaging features for biomarker-guided drug development Register now to gain invaluable insights in Parkinson's disease research: https://lnkd.in/ejzA2FtR hashtag#ParkinsonsResearch hashtag#EndpointDataCollection hashtag#Webinar

Last call! Don't miss out on our May 16 webinar exploring Parkinson’s disease endpoint data collection! Our experts will delve into topics that include: -Sensitivity of digital measures in disease progression monitoring -Efficacy and quality of life evaluations using clinical scales and patient-reported outcomes -Imaging features for biomarker-guided drug development Register now to gain invaluable insights in Parkinson's disease research: https://lnkd.in/eDbq5pAa hashtag#ParkinsonsResearch hashtag#EndpointDataCollection hashtag#Webinar

I am happy to share our recent publication entitle ''Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach'' in Current Diabetes Reviews (Bentham Science). Impact factor: 3.3

Rare disease research faces a common challenge: how do you study new treatments and advance research when there aren’t a lot of people living with the rare disease? And how do you incentivize drug development sponsors to invest in these important studies and encourage patients to participate in clinical trials?

Rare disease research faces a common challenge: how do you study new treatments and advance research when there aren’t a lot of people living with the rare disease? And how do you incentivize drug development sponsors to invest in these important studies and encourage patients to participate in clinical trials?

Rare disease research faces a common challenge: how do you study new treatments and advance research when there aren’t a lot of people living with the rare disease? And how do you incentivize drug development sponsors to invest in these important studies and encourage patients to participate in clinical trials?

Did you know that dyskinesia is a common complication from long-term treatment of Parkinson’s disease with levodopa? In Parkinson's disease, the signaling via dopamine receptors of the D1 and D2 types is impaired, which is counteracted by treatment with the standard of care, levodopa. However, after a few years, long-term treatment with levodopa causes neurons to express another type of dopamine receptor—D3. This disturbs the balance between the different dopamine types of receptors and leads to levodopa-induced dyskinesia (LID), a form of distressing involuntary movements.     IRLAB's pipeline currently includes five drug candidates, all of which have the potential to revolutionize the treatment of Parkinson's disease. Four of them target the symptoms that have the greatest impact on function and quality of life, for example, dyskinesia. The fifth is developed as a new treatment for the basic symptoms of Parkinson’s.    Follow us to learn more about Parkinson’s disease and our pipeline!    #parkinsonsdisease #dyskinesia #irlabtherapeutics #drugdiscovery #innovation 

Last call! Don't miss out on our May 16 webinar exploring Parkinson’s disease endpoint data collection! Our experts will delve into topics that include: -Sensitivity of digital measures in disease progression monitoring -Efficacy and quality of life evaluations using clinical scales and patient-reported outcomes -Imaging features for biomarker-guided drug development Register now to gain invaluable insights in Parkinson's disease research: https://lnkd.in/dcbRjgVt hashtag#ParkinsonsResearch hashtag#EndpointDataCollection hashtag#Webinar